Company Insights

XOMAO customer relationships

Explore interactive graphBrowse insights index
XOMAO customer relationship map

XOMA Corporation (XOMAO): customer relationships that move the royalty book

XOMA operates as a biotech royalty aggregator and IP licensor, monetizing its asset base through a mix of licenses, milestone and royalty payments, and the sale or purchase of future revenue streams. The company’s commercial model converts development-stage and marketed biopharma assets into predictable cash flows via licensing deals, royalty-sharing transactions and contingent value arrangements. For investors, XOMA’s value hinges on the durability of those cash flows and the counterparty profiles that underwrite them.

If you want a concise dashboard of XOMA’s counterparty links and commercial posture, see the firm’s public intel at https://nullexposure.com/.

How XOMA gets paid: concentrated, licensing-led cash conversion

XOMA’s 2024 Form 10‑K describes revenue sources as income from purchased receivables (RPAs, AAAs, CPPAs), licenses of intellectual property, and milestone and royalty income. This mix signals an operating model focused on converting IP into near- and long-term revenue streams rather than routine product sales. The company reports material activity across the U.S., Europe and Asia Pacific, underpinning a geographically diversified royalty book.

  • Contracting posture: Licensing and royalty-sharing predominate; XOMA acts as both licensor and buyer/seller of future streams.
  • Revenue concentration and criticality: A small number of large counterparties can drive outsized cash flow swings; counterparties’ commercial success directly determines royalties.
  • Maturity profile: The portfolio contains both marketed assets (near-term royalties) and development-stage programs (milestone-dependent upside), creating a blend of predictable income and event-driven cash inflections.

Explore XOMA relationship analytics in depth at https://nullexposure.com/.

What each material counterparty relationship actually is

Below I summarize every customer/partner relationship disclosed in the provided results, with source references for verification.

Janssen — non‑exclusive license (FY2024)

XOMA granted Janssen a non‑exclusive license to develop and commercialize certain product candidates, establishing a development and potential milestone/royalty pathway tied to those candidates. This is documented in XOMA’s 2024 Form 10‑K (filed December 31, 2024).

Medexus Pharmaceuticals, Inc. — IXINITY revenue stream & milestone rights (FY2024)

XOMA describes a transaction involving a stream and a portion of the milestone rights to IXINITY, a recombinant coagulation factor IX product marketed by Medexus, representing a surrendered share of future receipts in exchange for immediate consideration. The disclosure is in XOMA’s 2024 Form 10‑K (filed December 31, 2024).

Takeda — strategic royalty‑sharing and amended obligations (FY2025)

XOMA Royalty entered a strategic royalty‑sharing transaction with Takeda that reduced Takeda’s royalty and milestone obligations tied to mezagitamab, while XOMA Royalty will receive low‑ to mid‑single‑digit royalties and milestone payments across a basket of nine development‑stage assets in Takeda’s externalized portfolio. This was reported in a March 2026 press release and covered in The Globe and Mail/GlobeNewswire (March 2026).

Bristol Myers Squibb — contingent value right exposure via Repare deal (FY2025)

As part of XOMA’s acquisition of Repare, the company structured a contingent value right (CVR) that transfers 75–90% of net proceeds from Repare’s existing collaborations with Bristol Myers Squibb, among others, to XOMA; this ties XOMA’s recoveries to the monetization of those collaborations. OncologyPipeline covered the transaction in March 2026.

Debiopharm — included in Repare CVR waterfall (FY2025)

Debiopharm is one of the existing collaborators whose net proceeds from Repare collaborations are allocated to XOMA under the CVR framework, meaning future monetizations involving Debiopharm drive contingent upside for XOMA. This structure is described in coverage of XOMA’s Repare acquisition on OncologyPipeline (March 2026).

DCX Therapeutics — included in Repare CVR waterfall (FY2025)

DCX Therapeutics likewise features in the Repare acquisition’s CVR allocation, where a material share of net proceeds from existing DCX collaborations flows to XOMA under the contingent payment mechanics reported by OncologyPipeline (March 2026).

Roche — commercial payments tied to VABYSMO via CPPA (FY2024)

Under an Affitech CPPA, XOMA is eligible to receive 0.5% of net sales of VABYSMO for a ten‑year period following first commercial sale in each jurisdiction, creating a long‑dated low-single‑digit royalty stream linked to Roche’s commercialization of that product. This is disclosed in XOMA’s 2024 Form 10‑K (filed December 31, 2024).

What these relationships imply for investors

Collectively, these counterparty ties illustrate a portfolio strategy that blends near-term marketed royalties with development-stage contingent upside. Key investor takeaways:

  • Revenue defensibility is counterparty‑linked. XOMA’s cash flows are directly correlated with the commercial outcomes of Roche, Takeda and marketed products such as IXINITY; preservation of those revenue streams depends on partners’ sales execution and clinical progress.
  • Event-driven upside exists but is lumpy. The Takeda royalty‑sharing and Repare CVR create optionality that can produce material inflections if development programs or licensing funnels convert to cash.
  • Global footprint reduces single‑market risk but increases exposure to multinational licensing negotiations and jurisdictional commercialization dynamics.
  • Contracting sophistication is high. The presence of RPAs, CPPAs and CVRs points to a firm comfortable structuring bespoke financial and licensing instruments to extract value from IP.

You can get a structured view of these relationship mechanics and counterparty credit signals at https://nullexposure.com/.

Operational constraints and company‑level signals

XOMA’s public filings and disclosures provide company‑level signals rather than relationship‑specific qualifiers:

  • Licensing is the dominant contract type, supported by explicit disclosure of license revenues and historical license agreements (company 10‑K).
  • Geographic revenue is global with primary concentration in North America, Europe and Asia Pacific—this matters for regulatory and commercial variance across jurisdictions.
  • Role flexibility: XOMA acts both as licensor (granting rights to third parties) and as a purchaser/holder of royalty streams, reflecting an asset‑management posture rather than a pure R&D or product‑sales company.

These signals explain why investors should evaluate both counterparty clinical/commercial prospects and the structural terms of deals (royalty rates, duration, CVR waterfalls, and clawback provisions).

Bottom line and next steps

XOMA’s balance sheet and valuation hinge on the quality and enforceability of its royalty and license contracts, plus the near‑term commercialization prospects of partner drugs and the payout mechanics embedded in CVRs and CPPAs. For investors, focus on counterparty credit, product commercialization trajectories (especially Roche and Takeda exposures), and the contingent triggers embedded in the Repare acquisition.

For a deeper read on these relationships and how they affect risk-adjusted cash flows, visit https://nullexposure.com/.

If you want regular monitoring of XOMA’s customer and royalty relationships, including alerts on material amendments or monetization events, start with the XOMA profile at https://nullexposure.com/.